Navigation Links
DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of,Improved Glycemic Control and Significant Reductions of,LDL-Cholesterol and C-Reactive Protein

Top Line Data for the Treatment of Type 2 Diabetes Presented at the 67th Annual Scientific Sessions of American Diabetes Association

SAN FRANCISCO, June 25, 2007 /PRNewswire/ -- DiObex, Inc., a privately-held biopharmaceutical company focused on the development of therapeutics to treat metabolic diseases, today announced the presentation of top line data of its phase 2a study of DIO-902, a first-in-category Cortisol Synthesis Inhibitor for the treatment of type 2 diabetes.

Results of the two week placebo-controlled, dose-ranging study demonstrated that in patients treated with DIO-902 there was a trend toward improved glycemic control as measured by HbA1c, fructosamine and fasting blood glucose, as well as significant dose-dependent reductions in total and LDL- cholesterol. Mean levels of C-reactive protein (a marker of cardiovascular inflammation) were also significantly reduced in a dose-dependent fashion. Besides glycemic control, the additional benefits provided by DIO-902 may allow type 2 diabetes patients to manage their disease with fewer medications.

The data was presented at the 67th Annual Scientific Sessions of the American Diabetes Association (ADA) in Chicago, IL by Sherwin Schwartz, MD, lead investigator from the Diabetes and Glandular Disease Clinic of San Antonio, Texas. In his oral presentation, Dr. Schwartz detailed the results of the recently completed multi-center, randomized, placebo-controlled trial of DIO-902 in patients with type 2 diabetes.

"DIO-902 was well tolerated and we saw early signals of improvements in glycemic control," said Dr. Schwartz. "In addition, DIO-902 also showed early indications of potential to reduce the risk of heart disease through the significant reduction of LDL-cholesterol by as much as 46 percent at the highest dose studied. The prospect of a single therapeutic which has the potential to address multiple co-morbidities is very exciting."<
'"/>




Page: 1 2 3

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
11. Solstice Neurosciences Presents Escalating Dose Study at International Congress in Istanbul, Turkey
Post Your Comments:
(Date:9/30/2014)... , Sept. 30, 2014 Aileron ... Summary Global Markets Direct,s, ,Aileron Therapeutics, ... an overview of the Aileron Therapeutics, Inc.,s pharmaceutical ... comprehensive information on the current therapeutic developmental pipeline ... at various stages, therapeutics assessment by drug target, ...
(Date:9/30/2014)... -- According to their CEO, Rob Bohacs ... going through a complete transformation with highly targeted ... current clinical trial management process isn,t configured to ... which will ultimately drive the prescription cancer drugs ... been recognized by the National Cancer Institute as an ...
(Date:9/30/2014)... LOS ANGELES , Sept. 30, 2014   ... apnea shopping destination , today announced that it now ... ResMed . AirSense CPAPs are the first sleep apnea ... makes it simple and easy to track and share ... the overall effectiveness of their CPAP therapy.  In addition, ...
Breaking Medicine Technology:Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3Small Denver Company Pharmatech driving a large revolution in how cancer clinical trials are managed 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4
... Dec. 6, 2011 Talyst, a leader in ... American Society of Health-System Pharmacists (ASHP) Midyear Clinical ... access and secure management of CII medications. AutoVault ... restocking of controlled substance inventory. AutoVault ...
... The report " Active Pharmaceutical Ingredient (API) Market ... analyzes and studies the major market drivers, restraints, and opportunities ... Rest of the world. Browse market ... Pharmaceutical Ingredient (API) Market Trends, Competitive Landscape and Global Forecasts ...
Cached Medicine Technology:Talyst Unveils AutoVault™ at ASHP 2011 2MarketsandMarkets: API Market is Expected to Reach $159.08 Billion by 2016 2MarketsandMarkets: API Market is Expected to Reach $159.08 Billion by 2016 3
(Date:9/30/2014)... Irvine, Calif., Sept. 30, 2014 Research by UC ... system functions, shedding light on a vital process that ... , In the online version of Nature Immunology ... Zhou and other Institute for Immunology colleagues describe a ... and released into the bloodstream. , A T cell ...
(Date:9/30/2014)... University of Maryland-led research team has been awarded ... Institutes of Health (NIH) to develop new imaging ... our understanding of how large networks of neurons ... This knowledge will help researchers identify the precise ... behavior, like decision-making and speaking, and alterations in ...
(Date:9/30/2014)... September 30, 2014 EverStryke , the ... introduction to SurvivalLife.com along with a free book and class ... of Shane Michaels, prompting an investigative review. , “Joe ... in the survival and preparation niche, and this product is ... great classes and survival products that Joe offers on his ...
(Date:9/30/2014)... 2014 Elevate , the latest product ... in and out of the gym by providing natural ingredients ... attention of Shane Michaels, prompting an investigative review. , ... reason most people simply just don’t have the ability to ... at work, getting the motivation to finish a project, or ...
(Date:9/30/2014)... Los Angeles, CA (PRWEB) September 30, 2014 ... plastic surgery providers in Turkey has gone up more ... of growth. The medical tourism company also reported total ... since October 2012. , The company’s professional strategy has ... in Turkey — ultimately designed for patient comfort and ...
Breaking Medicine News(10 mins):Health News:UCI study uncovers important process for immune system development 2Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:EverStryke: Review Exposes Joe Marshall’s Permanent Match Survival Product 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4
... researchers have found that yo-yo dieting can more than double ... dieting, also known as weight cycling, is a repeated loss ... ,Researchers studied 140,057 women aged between 50 and ... yo-yo dieting and compared women average waist size to those ...
... have found that symptoms in patients with obstructive sleep ... with nasal insufflation (TNI), using a nasal cannula ... rate. ,Our findings provide evidence that TNI ... obstructive hypopneas and apneas, said lead researcher Hartmut Schneider, ...
... Patients with Chronic Obstructive Pulmonary Disease (COPD) are increasingly ... disease , but a new study finds that the ... be hospitalized for pneumonia. ,In a large ... inhaled corticosteroid use was associated with a significant 70 ...
... to open FatBurger fast food joint in Miami, Florida . ... South Beach diner revealed that she has been hooked to ... college. ,"That was part of my L.A. education ... all these low-riders (cars)... FatBurger was, like, the centrepiece for ...
... flowing in two of China's longest rivers -- the Yangtze ... change linked to the contraction of wetlands, warned the ... at the Chinese Academy of Sciences (CAS) as saying after ... wetlands on the Tibetan Plateau had shrunk by over 10 ...
... Actor/comedian Eddie Murphy is the worlds biggest love-rat, according to ... who has been named by Mel Bs pal Victoria Beckham ... callous way after she got pregnant with his child, topped ... Nutty Professor actor insisted on a DNA test to prove ...
Cached Medicine News:Health News:Nasal Cannula Treatment for Sleep Apnea Patients 2Health News:Nasal Cannula Treatment for Sleep Apnea Patients 3Health News:Patients Taking Inhaled Steroids may Develop Pneumonia 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: